Basilea seen up after raising 2026 guidance

Basilea Pharmaceutica AG, Allschwil

27/10/2026 07:43

** Shares in Basilea BSLN.S are seen up 7% in pre-market indications after the Swiss biotech company raised its 2026 revenue and operating profit guidance
** The company now expects operating profit of CHF 115 mln (€124 mln), up from CHF 70 mln previously, and revenue of about CHF 310 mln
** Basilea also raised its cash flow target for 2026-2030 and its 2030 financial targets
** Up to the previous session's close, the stock was up 26%​ YTD
     
     
(1 euro = 0.9248 Swiss francs)

 (Reporting by Aleksandra Kret in Gdansk)
 ((aleksandra.kret@thomsonreuters.com))